Thrombotic Microangiopathy in Cancer

Abstract

Thrombotic microangiopathy (TMA) is a rare but often devastating complication of cancer and cancer treatment. The syndrome is defined by thrombocytopenia (i.e., a platelet count of < 150,000/mcL or > 30% decrease from baseline), microangiopathic hemolytic anemia, and some evidence of organ damage. Among the nine recognized groups of disorders causing TMA, the focus of this article will be on cancer and cancer treatment-related causes of TMA. This review will discuss the pathophysiology of TMA in cancer, chemotherapy-associated TMA, transplant-associated TMA, and newer therapeutic modalities.

Keywords

thrombotic microangiopathy - cancer - hematopoietic stem cell transplantation - eculizumab

Addendum

This review represents a more comprehensive and updated review to one recently published by this author.[74] Some short excerpts of text have been reproduced with the permission of the publisher.[74]

• References

• 1 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347 (08) 589-600
• 2 George JN, Nestor CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371: 54-66
• 3 Brain MC, Azzopardi JG, Baker LR, Pineo GF, Roberts PD, Dacie JV. Microangiopathic haemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol 1970; 18 (02) 183-193
• 4 Lohrmann HP, Adam W, Heymer B, Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 1973; 79 (03) 368-375
• 5 Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979; 58 (05) 377-384
• 6 Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26 (03) 243-254
• 7 Francis KK, Kojouri K, George JN. Occult systemic carcinoma masquerading as thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Community Oncol 2005; 2: 339-343
• 8 Lesesne JB, Rothschild N, Erickson B. , et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7 (06) 781-789
• 9 Story M, Kwon SK, Robinson R, Fortis S. Acute cor pulmonale due to pulmonary tumour thrombotic microangiopathy from renal cell carcinoma. BMJ Case Rep 2017; 2017: bcr-2017-bcr-219730
• 10 von Herbay A, Illes A, Waldherr R, Otto HF. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer 1990; 66 (03) 587-592
• 11 Marumo S, Sakaguchi M, Teranishi T, Higami Y, Koshimo Y, Kato M. Pulmonary tumor thrombotic microangiopathy induced by ureteral carcinoma: a necropsy case report. Case Rep Oncol 2014; 7 (02) 605-610
• 12 Patrignani A, Purcaro A, Calcagnoli F, Mandolesi A, Bearzi I, Ciampani N. Pulmonary tumor thrombotic microangiopathy: the challenge of the antemortem diagnosis. J Cardiovasc Med (Hagerstown) 2014; 15 (11) 828-833
• 13 Dean SA, Mathis B, Litzky LA, Hood IC. Sudden death by occult metastatic carcinoma. J Forensic Sci 2015; 60 (06) 1637-1639
• 14 Abe H, Hino R, Fukayama M. Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer. Virchows Arch 2013; 462 (05) 523-531
• 15 Hotta M, Ishida M, Kojima F, Iwai Y, Okabe H. Pulmonary tumor thrombotic microangiopathy caused by lung adenocarcinoma: case report with review of the literature. Oncol Lett 2011; 2 (03) 435-437
• 16 Zwicker JI, Liebman HA, Neuberg D. , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
• 17 Ishida Y, Yamashita K, Sasaki H. , et al. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett 2008; 271 (01) 167-177
• 18 Suryawanshi S, Huang X, Elishaev E. , et al. Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res 2014; 20 (23) 6163-6174
• 19 Sussman T, Abazeed M, McCrae K, Khorana AA. RNA sequencing approaches to identifying novel biomarkers for thromboembolism (VTE) in lung cancer. Blood 2017; 130: 291
• 20 Khan MA, Assiri AM, Broering DC. Complement and macrophage crosstalk during process of angiogenesis in tumor progression. J Biomed Sci 2015; 22 (01) 58
• 21 Nunez-Cruz S, Gimotty PA, Guerra MW. , et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012; 14 (11) 994-1004
• 22 Davila M, Amirkhosravi A, Coll E. , et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008; 6 (09) 1517-1524
• 23 Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5 (01) 70-74
• 24 Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006; 32 (01) 33-39
• 25 Krisinger MJ, Goebeler V, Lu Z. , et al. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012; 120 (08) 1717-1725
• 26 Huber-Lang M, Sarma JV, Zetoune FS. , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (06) 682-687
• 27 Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96 (12) 1233-1239
• 28 Zipfel PF, Hallström T, Riesbeck K. Human complement control and complement evasion by pathogenic microbes--tipping the balance. Mol Immunol 2013; 56 (03) 152-160
• 29 Ritis K, Doumas M, Mastellos D. , et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177 (07) 4794-4802
• 30 Landsem A, Nielsen EW, Fure H. , et al. C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clin Exp Immunol 2013; 173 (02) 217-229
• 31 Griffin PT, Jaglal M. Metastatic prostate cancer mimicking thrombotic thrombocytopenic purpura. Blood 2015; 125 (08) 1349
• 32 Verweij J, van der Burg ME, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8 (01) 33-41
• 33 Grangé S, Coppo P. ; Centre de référence des microangiopathies thrombotiques (CNR-MAT). Thrombotic microangiopathies and antineoplastic agents. Nephrol Ther 2017; 13 (Suppl. 01) S109-S113
• 34 Izzedine H, Isnard-Bagnis C, Launay-Vacher V. , et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant 2006; 21 (11) 3038-3045
• 35 Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007; 8 (07) 634-641
• 36 Thurnher D, Kletzmayr J, Formanek M. , et al. Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001; 61 (02) 143-146
• 37 Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 1989; 64 (05) 1017-1020
• 38 Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23 (01) 247-253
• 39 Izzedine H, Escudier B, Lhomme C. , et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 2014; 93 (24) 333-339
• 40 Eremina V, Jefferson JA, Kowalewska J. , et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358 (11) 1129-1136
• 41 Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy, and reversible leukoencephalopathy. Ann Oncol 2007; 18 (10) 1745-1747
• 42 Martino S, Daguindau E, Ferrand C. , et al. A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib. Leuk Res Rep 2013; 2 (01) 29-31
• 43 Ojeda-Uribe M, Merieau S, Guillon M. , et al. Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. J Oncol Pharm Pract 2016; 22 (02) 361-370
• 44 Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat 2008; 40 (04) 211-213
• 45 Faguer S, Huart A, Frémeaux-Bacchi V, Ribes D, Chauveau D. Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 2013; 6 (05) 484-485
• 46 Al Ustwani O, Lohr J, Dy G. , et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 2014; 5 (01) E30-E33
• 47 Weitz IC, Deloughrey T. Effective treatment of chemotherapy induced atypical haemolytic uraemic syndrome with eculizumab: a case series of 7 treated patients. Brit J Hematol 2018; 183 (01) 136-139
• 48 Sartelet H, Toupance O, Lorenzato M. , et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5 (10) 2441-2447
• 49 Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology 2018; 73 (06) 990-1001
• 50 Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009; 122 (04) 322-328
• 51 Eremina V, Sood M, Haigh J. , et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111 (05) 707-716
• 52 Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8 (05) 286-293
• 53 Catalan SR, Yang S, Wu H. The use of ADAMTS13, platelet count and serum creatinine to differentiate acquired TTP and other thrombotic microangiopathies. Br J Haematol 2012; 157: 493-516
• 54 Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JAK, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3 (07) 1432-1436
• 55 Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125 (04) 616-618
• 56 Reese JA, Bougie DW, Curtis BR. , et al. Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol 2015; 90 (05) 406-410
• 57 Sartain S, Shubert S, Wu MF. , et al. Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience. Biol Blood Marrow Transplant 2018
• 58 Shayani S, Palmer J, Stiller T. , et al. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013; 19 (02) 298-304
• 59 Labrador J, López-Corral L, López-Godino O. , et al. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant 2014; 49 (05) 684-690
• 60 Glezerman IG, Jhaveri KD, Watson TH. , et al. Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16 (07) 976-984
• 61 Laskin BL, Maisel J, Goebel J. , et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation 2013; 96 (02) 217-223
• 62 Jodele S, Dandoy CE, Myers K. , et al. High dose Carboplatin/Etoposide/Melphalan increases the risk of thrombotic microangiopathy and organ damage after autologous stem cell transplantation. Bone Marrow Transplant 2018; 53 (10) 1311-1318
• 63 Rotz SJ, Luebbering N, Dixon BP. , et al. In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy. Blood Adv 2017; 1 (20) 1632-1634
• 64 Jodele S, Laskin BL, Dandoy CE. , et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015; 29 (03) 191-204
• 65 Gavriilaki E, Sakellari I, Batsis I. , et al. Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018; 32 (09) e13371
• 66 Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thromb Hemost 2016; 22 (01) 12-20
• 67 Laskin BL, Goebel J, Davies SM. , et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant 2011; 46 (05) 682-689
• 68 Jodele S, Davies SM, Lane A. , et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014; 124 (04) 645-653
• 69 Ostronoff M, Ostronoff F, Calixto R. , et al. Life- threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant an allogeneic bone marrow transplant recipient. Bone Marrow Transplant 2007; 39: 649-651
• 70 Corti P, Uderzo C, Tagliabue A. , et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 29 (06) 542-543
• 71 Jodele S, Licht C, Goebel J. , et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013; 122 (12) 2003-2007
• 72 Jodele S, Zhang K, Zou F. , et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016; 127: 989-996
• 73 Jodele S, Fukuda T, Vinks A. , et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20 (04) 518-525
• 74 Weitz IC. Thrombotic microangiopathy in cancer. Thromb Res 2018; 164 (Suppl. 01) S103-S105